Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02275117 · ClinicalTrials.gov registry record · Phase 2
A Multicenter Assessment of ALD403 in Chronic Migraine
A Phase 2 study, sponsored by Alder Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 665
- Enrollment target
NCT02275117 is a Phase 2 study that has completed, run by Alder Biopharmaceuticals. The registered enrollment target is 665 participants.
The verdict
NCT02275117, a Phase 2 study, has completed, sponsored by Alder Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 665 participants
- Enrollment target
Study Summary
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ALD403
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 665 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02275117
The ClinicalTrials.gov registry entry for NCT02275117 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 665 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alder Biopharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02275117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02275117 about?
NCT02275117 is a clinical study titled "A Multicenter Assessment of ALD403 in Chronic Migraine". The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
What is the current status of trial NCT02275117?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 665 participants. The study started on 2014-10. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02275117?
The interventions under investigation include: Placebo (BIOLOGICAL), ALD403 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02275117?
This trial is sponsored by Alder Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.